Jazz Pharmaceuticals plc

NASDAQ:JAZZ  
148.50
-1.03 (-0.69%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)9.19B
Current PEN/A
Forward PE 8.71
2yr Forward PE 8.46
See more stats
Estimates Current Quarter
Revenue$906.94 Million
Adjusted EPS$4.23
See more estimates
10-Day MA$149.02
50-Day MA$157.49
200-Day MA$141.07
See more pivots

Jazz Pharmaceuticals plc Stock, NASDAQ:JAZZ

Waterloo Exchange, Waterloo Road, Dublin, Dublin 4
Ireland
Phone: +353.1.634.7800
Number of Employees: 3200

Description

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.